drug
olaparib
Marketedupdated 5mo agoby AstraZeneca Pharmaceuticals LP
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(1)
Trials studying olaparib
- phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- phase2Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
- phase2Olaparib With Ceralasertib in Recurrent Osteosarcoma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase3Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- phase3Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
- phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- phase2A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 27, 2026
81 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (25)
- Oct 25, 2041method-of-use (U-3931)US 11970530
- Oct 25, 2041method-of-use (U-3931)US 11970530
- Aug 4, 2031method-of-use (U-2480)US 88595624.8y
- Aug 4, 2031method-of-use (U-3333)US 88595624.8y
- Aug 4, 2031method-of-use (U-1634)US 88595624.8y
- Dec 31, 2029formulationUS 84758423.2y
- Dec 31, 2029formulationUS 84758423.2y
- Oct 7, 2029formulationUS 116333963.0y
- Oct 7, 2029formulationUS 116333963.0y
- Oct 7, 2029formulationUS 119750013.0y
- Oct 7, 2029formulationUS 119750013.0y
- Oct 7, 2029formulationUS 120486953.0y
- Oct 7, 2029formulationUS 120486953.0y
- Oct 7, 2029formulationUS 121448103.0y
- Oct 7, 2029formulationUS 121448103.0y
- Oct 7, 2029formulationUS 121788163.0y
- Oct 7, 2029formulationUS 121788163.0y
- Sep 24, 2028compositionUS 82474162.0y
- Sep 8, 2027compositionUS 7449464336d
- Sep 8, 2027compositionUS 7449464336d
- Aug 12, 2027method-of-use (U-2822)US 8071579309d
- Aug 12, 2027method-of-use (U-3333)US 8071579309d
- Aug 12, 2027method-of-use (U-1634)US 8143241309d
- Aug 12, 2027method-of-use (U-3333)US 8143241309d
- Aug 12, 2027method-of-use (U-3333)US 8143241309d
FDA exclusivities (6)
- May 8, 2027ODE-306Orphan Drug (7y)213d
- May 8, 2027ODE-306Orphan Drug (7y)213d
- Dec 27, 2026ODE-283Orphan Drug (7y)81d
- Dec 27, 2026ODE-283Orphan Drug (7y)81d
- May 31, 2026I-914Indication (3y)
- May 31, 2026I-914Indication (3y)
News(2)
- ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal everIf AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.biospace · 2mo ago
- Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsWith a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.biospace · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that